Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Revenue Recognition

Not if the settlement is contingent on the USPTO re-validation of the patents. Remember that Toshiba was the one that originally requested the re-examination. Judge Ward is still holding onto the MOU for a reason. IMO there is more behind the curtain than what meets the eyes at this point in time. We will never know what the J's really will end up paying, but we should see money in the future providing the re-validation is found in our favor in the Q reports and if I can get a little better clarification on the royalty payment question, IMO that is a sign of great thiongs to come.

I think I've reached my limit on posting for the day. Sorry everyone.

All the best,

Steve

Share
New Message
Please login to post a reply